Trajan Group Holdings Ltd · ASX:TRJ
Trajan — H1 2022 Earnings Presentation
18 slides from Trajan's earnings presentation, Feb 24, 2022
Slide 1: 1H FY22 Trading Update
1H FY22 Trading Update Stephen Tomisich CEO and Managing Director 24th February 2022 Science that benefits people
Slide 2: Science that benefits people: our values
Respect Through our values and actions, we aim to Integrity impact human wellbeing in a meaningful way. Discipline Empowerment Science Sciencethat thatbenefits benefitspeople people
Slide 3: 1H FY22 Highlights
1H FY22 Highlights Science that benefits people Underlying revenue growth, EBITDA in line with plan 2.1 % $43.7M 20.6%1 $4.8M Gross Profit Total Revenue Normalised Margin Revenue Growth EBITDA Expansion2 • Both business segments contributed growth. • Organic growth of 12.8% on a constant currency ba
Slide 4: Full Year FY22 Forecast Guidance
Full Year FY22 Forecast Guidance Science that benefits people $104.0M $12.5M • Organic growth forecast at high single digit rate in 2H FY22. to to • Contributions from acquisitions to step up in 2H $110.0M $13.5M FY22. Total Revenue Normalised • Forecasting relatively broad revenue and normalised ra
Slide 5: 1H FY22 Operational Update
Science that benefits people 1H FY22 Operational Update Science that benefits people
Slide 6: Strong Product and Customer Growth
Strong Product and Customer Growth Science that benefits people • Strong growth in strategic product lines; fluidic devices, proteomics-related growth drivers in tubing, and HDX. • Consistent growth across the product portfolio with several product lines achieving circa 50%. • Strategic chromatograp
Slide 7: IPO Use of Funds
IPO Use of Funds Science that benefits people Funds Raised Funds Deployed $18.7M Strategic acquisitions and investments $23.5M $26.5M Unused IPO Deployed IPO Funds Funds $7.1M Capital raise and IPO costs $ 0.67 M Technology $ 0.04 M commercialisation Project Neptune IPO funds have been used to: • Su
Slide 8: Execution of M&A Strategy
Execution of M&A Strategy Science that benefits people From the individual to analytical information Added capability, platforms and customer sets to our laboratory automation business (November 2021). Created a leadership position in blood microsampling (December 2021). Invested in consumer health
Slide 9: Commercial Acceleration
Commercial Acceleration Science that benefits people • Following the MyHealthTest acquisition (March 2021), we’ve invested in 1H to rapidly build and resource an analytical laboratory in Melbourne, forming the basis of Trajan Analytical Services, “TAS”. • We are addressing the key barriers to broad
Slide 10: Validation of Blood Sampling is Building
Validation of Blood Sampling is Building Scientific Papers Featuring Mitra® and hemaPEN® Technologies Science that benefits people 100 90 80 70 60 # of papers 50 40 30 20 10 0 2014 2015 2016 2017 2018 2019 2020 2021 Now 200+ peer reviewed scientific papers published globally on Trajan microsampling
Slide 11: Microsampling Commercial Adoption
Microsampling Commercial Adoption Science that benefits people Trajan is now leading the way # of Mitra® and hemaPEN® Customers Mitra® and hemaPEN® Customers by Industry Purchasing per Year 700 6% 6% 600 37% 18% 500 400 300 33% 200 100 Clinical Dx Research Pharma Molecular DX Wellness 0 2016 2017 20
Slide 12: 1H FY22 Financials
Science that benefits people 1H FY22 Financials Science that benefits people
Slide 13: 1H FY22 Financials
1H FY22 Financials Science that benefits people Strong growth profile supported by successful strategic acquisitions Revenue ($M) & Gross Profit1 Margin% Normalised EBITDA ($M) & Normalised2 EBITDA Margin % The Group reported overall revenues for the half-year ended 31 December 2021 of $43.7M (2020:
Slide 14: 1H FY22 Segment breakdown
1H FY22 Segment breakdown Science that benefits people Diversified product mix delivering recurring revenue and significant growth opportunities Analytical Products Life Science Solutions • Reported revenue was up 12.6% on pcp and gross profit1 grew by $1.5M in the half year, up 14.0% • Reported rev
Slide 15: Acceleration of Margin Expansion
Acceleration of Margin Expansion Science that benefits people • “Project Neptune” has commenced. Forecast FY22 EBITDA impact remains neutral. • Additional resource added in Nov-Jan. • Some scheduled syringe transfers to MYS delayed in 1H due to COVID, will correct in 2H. • Total annual gross margin
Slide 16: Financial Outlook
Financial Outlook Science that benefits people FY23 $104.0M $12.5M to to $135.0M $110.0M $13.5M to Total Revenue Normalised $145.0M range EBITDA range Total Revenue range FY22 • Expecting continued revenue growth across a broad range of products and customers, with full impact of acquisitions to be
Slide 17: Q&A
Science that benefits people Q&A Science that benefits people
Slide 18: Disclaimer
Disclaimer Science that benefits people The material in this presentation is general background information about Trajan Group Holdings Limited (Trajan) and is current at the date of the presentation, 24 February 2022. The information in the presentation is provided for information purposes only, is
Trajan Group Holdings — H1 2022 Earnings Presentation on 6ix